Exciting New Data Presented At
2021 ASCO Annual Meeting
Agendia will present new data from ongoing clinical research evaluating the combination of MammaPrint and BluePrint genomic tests.
The data, which builds upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to support treatment planning decisions, highlights Agendia’s ongoing trials that have the potential to impact patient treatment and outcomes.
We invite you to meet our team via live chat. We can discuss genomic testing in the pre-operative setting, or answer any questions you might have.
Agendia’s activities:
Industry Expert Theater
Title: Expanding Knowledge and Driving Innovation in Breast Cancer
Speaker: William Audeh, MD
Breast Medical Oncologist, Agendia Chief Medical Officer
Description: This presentation will discuss new clinical data on MammaPrint and BluePrint’s clinical utility in patients with breast cancer as well as innovative developments within Agendia. We encourage audience participation, discussion and questions at the end of the presentation.
Clinical Data Highlights – Oral Presentations
Session Title: The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: A Focus on Equity in Breast Cancer Care
Presentation Title: Disparities within Luminal breast cancer: clinical and molecular features of African American and non-Hispanic White patients
Speaker: Kent Hoskins, MD
View Presentation
Session Title: Breast Cancer—Local/Regional/Adjuvant
Presentation Title: Utility of the 70-gene MammaPrint assay for prediction of benefit from (ELT) in the NRG Oncology/NSABP B-42 trial
Speaker: Priya Rastogi, MD
View Presentation
Presentation Title: Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial
Speaker: Josephine Lopes Cardozo, MD
View Presentation
Clinical Data Highlights – Poster Presentations
Title: Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint (Abstract #563)
Authors: Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12, William Audeh12, FLEX Investigators’ Group13
1. Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; 2. University of Texas San Antonio MD Anderson Cancer Center, San Antonio, TX; 3. City of Hope National Medical Center, Duarte, CA; 4. Vail Health Shaw Regional Cancer Center, Edwards, CO; 5. Rocky Mountain Cancer Center, US Oncology, Aurora, CO; 6. Baptist MD Anderson Cancer Center, Jacksonville, FL; 7. Nashville Breast Center, Nashville, TN; 8. New York Oncology Hematology-Albany, US Oncology, Albany, NY; 9. AMITA Health, Saint Alexis Medical Center, Bartlett, IL; 10. Texas Tech University Health Sciences Center, Breast Center of Excellence, Amarillo, TX; 11. Texas Oncology-Waco, US Oncology, Waco, TX; 12. Medical Affairs, Agendia, Inc., Irvine, CA; 13. FLEX Investigators’ Group
Title: Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years (Abstract #565)
Authors: Cathy Graham1, Douglas K. Marks2, Nina D’Abreo2, Sami Diab3, Vijayakrishna K. Gadi4, Midas M. Kuilman5, Andrea Menicucci6, Amy M. Truitt6, Shiyu Wang6, Patricia Dauer6, William Audeh6, FLEX Investigators’ Group8
1. Emory University School of Medicine, Atlanta, GA; 2. Perlmutter Cancer Center at NYU Langone Hospital-Long Island, Mineola, NY; 3. Rocky Mountain Cancer Center, US Oncology, Aurora, CO; 4. Fred Hutchinson Cancer Research Center, Seattle, WA; 5. Research and Development, Agendia NV., Amsterdam, Netherlands; 6. Medical Affairs, Agendia Inc., Irvine, CA; 8. FLEX Investigators’ Group
Title: Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer (Abstract #559)
Authors: Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5
1. Perlmutter Cancer Center at NYU Langone Hospital-Long Island, 2. NYU Long Island School of Medicine, Mineola, NY; 3. Medical Affairs, Agendia, Inc., Irvine, CA; 4. Research and Development, Agendia NV, Amsterdam, Netherlands 5. FLEX Investigators’ Group
Virtual Booth
Visit our virtual booth for more information and to speak with a member of our team.
Want more information?
Industry Expert Theater Speaker: William Audeh, MD
Description: This presentation will discuss new clinical data on MammaPrint and BluePrint’s clinical utility in patients with breast cancer as well as innovative developments within Agendia. We encourage audience participation, discussion and questions at the end of the presentation.
About the speaker: William Audeh, MD, MS is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program.
Speaker: Priya Rastogi, MD
Session Type: Oral Abstract Session
Track: Breast Cancer
Abstract: #500
Speaker: Josephine Lopes Cardozo, MD
Session Type: Oral Abstract Session
Track: Breast Cancer
Abstract: #502
Speaker: Kent Hoskins, MD
Session Type: Clinical Science Symposium
Track: Breast Cancer
Abstract: #1009
FOR PROVEN RESULTS
Trusted by leading physicians and institutions around the world
*Not an official event of the 2021 ASCO Annual Meeting
